Pfizer’s sickle cell disease candidate fails Phase III trial
This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.
18 August 2025
18 August 2025
This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.